ARTICLE | Clinical News
Yondelis trabectedin: Compassionate use program data
June 12, 2006 7:00 AM UTC
Data from a compassionate use study in 44 patients showed a long-lasting objective remission and tumor control in 86% of patients. Median progression-free survival was 18 months and median survival wa...